The University of Vermont The School of Business Administration |
Personnel Profile
 Paulette J. Thabault, JD
Part Time Lecturer
Ms. Thabault is the Commissioner of the Department of Banking, Insurance, securities and Health Care Administration for the state of Vermont.
The Commissioner is charged with regulating a broad spectrum of financial services industries in the banking, lending, insurance and securities arena, including a growing number of legislatively mandated programs relating to hospital budget oversight, health care quality improvement, and affordability of health care. In addition to regulatory oversight, BISHCA has programs for enforcement, direct consumer assistance and administrative complaint resolution. These functions commonly generate reparations of million of dollars annually to Vermont consumers. Vermont is also the premier captive insurance domicile in the country -- and ranks third in the world -- with over $10 billion in premiums annually.
The commissioner is charged with ensuring that regulated companies and institutions operate within the law; that they operate in a financially sound manner and thus remain able to deliver on earnings, benefits or services promised to consumers; that costs of services and benefits are reasonable for the marketplace; and that consumers are treated fairly -- in accordance with contractual agreements and all applicable consumer laws. BISHCA almost entirely self-funded, currently has a budget of over $14 million and annually returns millions of dollars to the General Fund stemming from industry fines and fees.
Publication History
Journal Article, Academic Journal
- Bauer, M.; Thabault, P.; Estok, D.; Christiansen, C.; Platt, R. - "Low-dose corticosteroids and avascular necrosis of the hip and knee" (Refereed)
- 2000 - v. 9, no. 3, pp. 187-91
[View publication]
[Show/Hide Abstract]
Abstract: BACKGROUND: Although high-dose corticosteroid use constitutes a well-known risk factor for avascular necrosis (AVN), the risk of AVN with low-dose corticosteroids is not well established. OBJECTIVE: To assess AVN risk for high-dose and low-dose oral corticosteroid exposure compared to baseline risk. METHODS: We employed a nested case-control study design. AVN of the hip and knee was determined from coded diagnoses and full text record review. Corticosteroid exposure was ascertained through outpatient automated pharmacy dispensing files. RESULTS: Thirty-one cases occurred during approximately 720,000 person years. Eleven of 22 cases that met all eligibility criteria received oral corticosteroids during the 3 years before diagnosis. There was a cumulative dose-related corticosteroid effect from no excess risk (relative risk=0.95% Confidence Interval=0-5) for doses 1-430 mg, to a relative risk of 6 (95% CI 1-43) for doses of 440-1290 mg, and an undefined relative risk (95% Lower CI 26) for doses greater than 1290 mg. CONCLUSIONS: Systemic corticosteroids were strongly associated with AVN, however, the effect was not clearly evident at 3-year cumulative doses
Book, Scholarly-New
- Thabault, P.; Carr - ""Non-Hormonal Contraception???"
- The Medical Care of Women
- 1995
, W.B. Saunders Company
|
|